Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

New challenges in endpoints for drug development in advanced melanoma.

Ribas A, Hersey P, Middleton MR, Gogas H, Flaherty KT, Sondak VK, Kirkwood JM.

Clin Cancer Res. 2012 Jan 15;18(2):336-41. doi: 10.1158/1078-0432.CCR-11-2323. Epub 2011 Dec 5.

2.

New targeted therapies in melanoma.

Kudchadkar RR, Gonzalez R, Lewis K.

Cancer Control. 2013 Oct;20(4):282-8. Review.

PMID:
24077404
3.

Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.

Dean E, Lorigan P.

Expert Rev Anticancer Ther. 2012 Nov;12(11):1437-48. doi: 10.1586/era.12.124. Review.

PMID:
23249108
4.

[Metastatic melanoma: some hope from ipilimumab and vemurafenib].

Piérard-Franchimont C, Piérard GE.

Rev Med Liege. 2012 Feb;67(2):64-8. French.

5.

Ipilimumab: from preclinical development to future clinical perspectives in melanoma.

Letendre P, Monga V, Milhem M, Zakharia Y.

Future Oncol. 2017 Mar;13(7):625-636. doi: 10.2217/fon-2016-0385. Epub 2016 Nov 24. Review.

6.

Vemurafenib in melanoma.

Shaw HM, Nathan PD.

Expert Rev Anticancer Ther. 2013 May;13(5):513-22. doi: 10.1586/era.13.24. Review.

PMID:
23617343
7.

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.

Kim A, Cohen MS.

Expert Opin Drug Discov. 2016 Sep;11(9):907-16. doi: 10.1080/17460441.2016.1201057. Epub 2016 Jun 23. Review.

8.

Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.

Lee D, Porter J, Hertel N, Hatswell AJ, Briggs A.

BioDrugs. 2016 Aug;30(4):307-19. doi: 10.1007/s40259-016-0178-1.

PMID:
27177756
9.

[Major therapeutic advances in the treatment of metastatic melanoma].

Mateus C, Robert C.

Bull Cancer. 2012 Jun;99(6):619-25. doi: 10.1684/bdc.2012.1594. Review. French.

10.

Vemurafenib and ipilimumab: new agents for metastatic melanoma.

Banaszynski M, Kolesar JM.

Am J Health Syst Pharm. 2013 Jul 15;70(14):1205-10. doi: 10.2146/ajhp120260. Review.

PMID:
23820456
11.

Vemurafenib for the treatment of BRAF mutant metastatic melanoma.

Martin-Liberal J, Larkin J.

Future Oncol. 2015;11(4):579-89. doi: 10.2217/fon.14.252. Review.

PMID:
25686114
12.

Current and future roles of targeted therapy and immunotherapy in advanced melanoma.

Olszanski AJ.

J Manag Care Spec Pharm. 2014 Apr;20(4):346-56. Review.

13.

Upcoming strategies for the treatment of metastatic melanoma.

Spagnolo F, Queirolo P.

Arch Dermatol Res. 2012 Apr;304(3):177-84. doi: 10.1007/s00403-012-1223-7. Epub 2012 Feb 17. Review.

PMID:
22350184
14.

Systemic therapy for metastatic melanoma in 2012: dawn of a new era.

Bhatia S, Thompson JA.

J Natl Compr Canc Netw. 2012 Mar;10(3):403-12. Review.

PMID:
22393198
15.

Current advances and perspectives in the treatment of advanced melanoma.

Livingstone E, Zimmer L, Vaubel J, Schadendorf D.

J Dtsch Dermatol Ges. 2012 May;10(5):319-25. doi: 10.1111/j.1610-0387.2012.07895.x. Epub 2012 Mar 20. Review.

16.

Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.

Heakal Y, Kester M, Savage S.

Ann Pharmacother. 2011 Nov;45(11):1399-405. doi: 10.1345/aph.1Q363. Epub 2011 Oct 25. Review.

PMID:
22028422
17.

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.

Camacho LH.

Cancer Med. 2015 May;4(5):661-72. doi: 10.1002/cam4.371. Epub 2015 Jan 25. Review.

18.

[New treatment options for metastatic melanoma].

Tietze JK, Berking C.

Dtsch Med Wochenschr. 2014 Jul;139(28-29):1462-7. doi: 10.1055/s-0034-1370155. Epub 2014 Jul 1. Review. German. No abstract available.

PMID:
24983194
19.

Cutaneous melanoma: new advances in treatment.

Foletto MC, Haas SE.

An Bras Dermatol. 2014 Mar-Apr;89(2):301-10. Review.

20.

Novel targets in the treatment of advanced melanoma: new first-line treatment options.

Culos KA, Cuellar S.

Ann Pharmacother. 2013 Apr;47(4):519-26. doi: 10.1345/aph.1R614. Epub 2013 Apr 2. Review.

PMID:
23548648

Supplemental Content

Support Center